| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BCRX | Common Stock | Award | $0 | +6,820 | +23% | $0.000000 | 36,431 | 12 Jun 2024 | Direct | F1, F2 |
| holding | BCRX | Common Stock | 21,940 | 12 Jun 2024 | By Trust | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BCRX | Automatic Stock Option Grant | Award | $0 | +49,933 | $0.000000 | 49,933 | 12 Jun 2024 | Common Stock | 49,933 | $6.30 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| F2 | The shares purchased by the reporting person on May 13, 2024 were inadvertently reported as being purchased directly by the reporting person but were actually purchased by the reporting person's trust. The reporting person is a trustee of such trust and the reporting person and members of his family are the sole beneficiaries of the trust. The reporting person is an indirect beneficial owner of the shares held by the trust. |
| F3 | Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |